UK News

NICE has recommended eight new digital therapies to be used by the NHS for the treatment of mental health disorders

Eli Lilly and AbbVie both announce that they will leave VPAS, causing concern that NHS patients may not receive breakthrough drug treatments

Merck has been planning a $1.3bn research hub in london for the last six years, but this will finally begin construction in April

The ECMC in Cambridge is one of a handful of organisations to receive a share of £47.5 funding over the next five years

The NHS will soon begin offering artificial pancreas to type 1 diabetes patients to help them manage their condition more effectively

ScotBio has announced "promising initial results" from its attempt to extract a cure for the common cold from algae

Researchers at UCL have begun looking into the impacts of ambroxol as a treatment for Parkinson's disease

Unison general secretary Christina McAnea said that the ongoing ambulance strikes will continue to go ahead without a “very firm commitment” on pay, as the Government has “adamantly refused” to engage in a “proper discussion” about pay rises.

GlaxoSmithKline has chosen to establish its new headquarters in London’s West End, on the corner of New Oxford Street and Earnshaw Street in the Capital’s centre. The new hub is expected to open in 2024.

UK-based point-of-care diagnostics company LumiraDx has been given $14m in grants from the Bill & Melinda Gates Foundation to support the ongoing development of its point-of-care molecular tuberculosis (TB) test system.

Japan-based Sosei Heptares announced that it has joined forces with UK global biopharma company Eli Lilly to discover, develop and commercialise small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with diabetes and metabolic diseases.

German biotech company BioNTech and the UK Government have signed a Memorandum of Understanding (MoU), which will accelerate clinical trials of personalised mRNA immunotherapies. It is hoped this acceleration will lead to up to 10,000 patients receiving such therapies by the end of 2030.